195 related articles for article (PubMed ID: 9354694)
21. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.
Gribben JG; Saporito L; Barber M; Blake KW; Edwards RM; Griffin JD; Freedman AS; Nadler LM
Blood; 1992 Aug; 80(4):1083-9. PubMed ID: 1498325
[TBL] [Abstract][Full Text] [Related]
22. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
23. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation.
Hardingham JE; Kotasek D; Sage RE; Dobrovic A; Gooley T; Dale BM
Bone Marrow Transplant; 1993 Jan; 11(1):15-20. PubMed ID: 8381694
[TBL] [Abstract][Full Text] [Related]
24. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Delage R; Soiffer RJ; Dear K; Ritz J
Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
27. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients.
Macintyre EA; Belanger C; Debert C; Canioni D; Turhan AG; Azagury M; Hermine O; Varet B; Flandrin G; Schmitt C
Blood; 1995 Dec; 86(12):4691-8. PubMed ID: 8541563
[TBL] [Abstract][Full Text] [Related]
28. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma.
McCann JC; Kanteti R; Shilepsky B; Miller KB; Sweet M; Schenkein DP
Biol Blood Marrow Transplant; 1996 Feb; 2(1):37-43. PubMed ID: 9078353
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
30. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
31. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
[TBL] [Abstract][Full Text] [Related]
32. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
[TBL] [Abstract][Full Text] [Related]
33. Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease.
Drobyski WR; Baxter-Lowe LA; Truitt RL
Blood; 1993 Jan; 81(2):551-9. PubMed ID: 8422472
[TBL] [Abstract][Full Text] [Related]
34. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
35. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.
Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N
Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958
[TBL] [Abstract][Full Text] [Related]
36. PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia.
Vervoordeldonk SF; Merle PA; Behrendt H; Steenbergen EJ; van den Berg H; van Wering ER; von dem Borne AE; van der Schoot CE; van Leeuwen EF; Slaper-Cortenbach IC
Br J Haematol; 1997 Feb; 96(2):395-402. PubMed ID: 9029032
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.
Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317
[TBL] [Abstract][Full Text] [Related]
38. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG
Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667
[TBL] [Abstract][Full Text] [Related]
39. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
40. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT.
Radich J; Ladne P; Gooley T
Biol Blood Marrow Transplant; 1995 Nov; 1(1):24-31. PubMed ID: 9118286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
